Vaginal Drug Delivery


The vagina has been studied as a favorable  site for the local and systemic delivery  of drugs and this route offers certain  advantages, such as avoidance of gut and  hepatic first pass metabolism, reduction  in gastrointestinal and hepatic side effects,  and local targeting of drugs to the  reproductive organs. Vaginally administered  agents and formulations are mainly  being developed to provide “dual prophylaxis”  for contraception and protection  against microbial infections including AIDS  and other sexually transmitted diseases  (STDs). Drug delivery technologies that  have been used for vaginal drug delivery  include the intravaginal ring (IVR) and  VagiSite bioadhesive technology.


    Related Conference of Vaginal Drug Delivery

    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    December 01-02, 2025

    13th International Conference on Clinical Trials

    Vancouver, Canada
    January 29-30, 2026

    19th World Drug Delivery Summit

    Paris, France
    February 10-11, 2026

    40th World Congress on Pharmacology and Therapeutics

    Barcelona, Spain
    February 23-24, 2026

    3rd World Congress on Biologics and Biosimilars

    London, UK
    March 23-24, 2026

    36th Annual European Pharma Congress

    London, UK
    March 24-25, 2026

    11th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    April 16-17, 2026

    19th European Biosimilars Congress

    Rome, Italy
    April 27-28, 2026

    9th European Biopharma Congress

    Paris, Aland Islands
    May 28-29, 2026

    3rd International Conference on Pharmacognosy

    Madrid, Spain
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy

    Vaginal Drug Delivery Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in